secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tango Therapeutics, Inc. (TNGX)
CIK:        0001819133
Form:       8-K
Filed at:   2026-10-23T10:36:06+00:00
Accession:  0001193125-26-429423
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Tango's vopimetostat+daraxonrasib shows 82% ORR in 2L/3L PDAC; Phase 3 planned, workforce cut 14%
--------------------------------------------------------------------------------

- Phase 1/2: 82% ORR (18/22) in 2L/3L MTAP-deleted/RAS-mutant PDAC; median PFS not reached, 88% 9-month PFS, 100% DCR at Aug 20, 2026 cutoff.
- Dose level 1 vopimetostat 200 mg + daraxonrasib 100 mg daily well tolerated: no DLTs, no Grade 4/5 TRAEs, Grade 3 TRAEs 40%; dose level 2 had 3 DLTs in 2 patients.
- FDA-aligned Phase 3 in front-line MTAP-deleted PDAC to randomize 1:1 vopimetostat+daraxonrasib vs standard chemotherapy, dual primary endpoints ORR and PFS, starting 1H 2027.
- Zoldonrasib combo in MTAP-deleted/KRAS G12D PDAC: 54% ORR (19/35), 61% 9-month PFS, 97% DCR; NSCLC daraxonrasib combo 80% ORR (4/5).
- Board approved Oct 22 strategic reprioritization: focus on PRMT5/vopimetostat/TNG456, halt certain preclinical work, cut workforce ~14%, mostly research.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819133/000119312526429423/0001193125-26-429423-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819133/000119312526429423/d151613d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-429423

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer